Grant-in-Aid for Scientific Research (A)
|Allocation Type||Single-year Grants |
Circulatory organs internal medicine
|Research Institution||Kyushu University |
SHIMOKAWA Hiroaki (2003) Kyushu University, Graduate School of Medical Sciences, Department of Cardiovascular Medicine, Associate Professor, 大学院・医学研究院, 助教授 (00235681)
竹下 彰 (2001-2002) 九州大学, 大学院・医学研究院, 教授 (30038814)
ITO masaaki Mie University, Dept.of Int.Med., Assistant Professor, 医学部, 講師 (00223181)
KAIBUCHI Kozo Nagoya University, Dept.of Cell Pharmacology, Professor, 大学院・医学研究科, 教授 (00169377)
SUEISHI Katsuo Kyushu University, Dept.of Pathophysiol.Exp.Pathology, Professor, 大学院・医学研究院, 教授 (70108710)
ICHIKI Toshihiro Kyushu University, Dept.of Cardiovasc Med., Assistant Professor, 助手 (80311843)
KOIKE George Kyushu University, Dept.of Cardiovasc Med., Assistant Professor, 助手 (90325522)
下川 宏明 九州大学, 大学院・医学研究院, 助教授 (00235681)
平川 洋次 九州大学, 医学部附属病院, 助手 (90332840)
|Project Period (FY)
2001 – 2003
Completed (Fiscal Year 2003)
|Budget Amount *help
¥54,990,000 (Direct Cost: ¥42,300,000、Indirect Cost: ¥12,690,000)
Fiscal Year 2003: ¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2002: ¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2001: ¥21,710,000 (Direct Cost: ¥16,700,000、Indirect Cost: ¥5,010,000)
|Keywords||Rho-kinase / Vasospastic angina / Atherosclerosis / Cardiac hypertrophy / Restenosis / Myocardial infarction / Heart failure / Pulmonary hypertension / Rho-kinase / Rho / 炎症 / 狭心症 / シグナル伝達 / 冠動脈攣縮 / 高血圧|
(1)We have demonstrated that Rho/Rho-kinase-mediated pathway plays an important role in the pathogenesis of hypertension.
(2)We have demonstrated that Rho-kinase-mediated pathway is substantially involved in the pathogenesis of angiotensin II-induced cardiovascular hypertrophy in rats.
(3)We have demonstrated that Rho-kinase is located downstream of PKC in the signal transduction of vascular smooth muscle for coronary spasm in a porcine model.
(4)We have demonstrated that long-term treatment with a Rho-kinase inhibitor suppresses the development of in-stent restenosis in porcine coronary arteries.
(5)We have demonstrated that long-term treatment with a Rho-kinase inhibitor suppresses the development of LV remodeling after myocardial infarction in mice through inhibition of the expression of inflammatory cytokines.
(6)We have demonstrated that long-term treatment with a Rho-kinase inhibitor suppresses the development of monocrotaline-induced pulmonary hypertension in rats.
(7)We have demonstrated that Rho-kinase is substantially mediated in the pathogenesis of microvascular angina.